Here we showed for the first time that LPAR2 has a pivotal role in maintaining intestinal mucosal integrity against NSAIDs, because the lack of LPAR2 accelerates the development of NSAID enteropathy, whereas selective activation of LPAR2 reduces the severity of intestinal mucosal injury. The gene discussed is LPAR2; the disease is Abnormal intestine morphology.